Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-04-27 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
第六届董事会第四十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Beijing Xinghao Pharmaceutical Co., Ltd. It details the convening and attendance of the 41st meeting of the 6th Board of Directors, including the approval of the company's 2025 Q1 report. The document references the actual quarterly report being disclosed on the Beijing Stock Exchange information platform with a separate announcement number (2025-067). The text itself does not contain the financial statements or substantive financial data of the quarterly report but rather announces the board's approval of that report. The document is short (929 characters) and serves as a formal announcement of the board meeting decisions, not the report itself. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management information.
2025-04-27 Chinese
独立董事候选人声明与承诺（周均）
Board/Management Information Classification · 95% confidence The document is a formal declaration and commitment statement by an independent director candidate (周均) for Beijing Xinghao Pharmaceutical Co., Ltd. It details the candidate's qualifications, compliance with relevant laws and regulations, and commitment to independence and duties as an independent director. There are no financial statements, earnings data, or report attachments. The document is a regulatory announcement related to board/management information, specifically about a director candidate's declaration and commitment. It does not fit into categories like Annual Report, Earnings Release, or Proxy Solicitation. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on management information, not a report publication or certification.
2025-04-22 Chinese
独立董事2024年度述职报告（程雪翔）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2024 Annual Work Report" for Beijing Xinghao Pharmaceutical Co., Ltd. It details the independent director's duties, attendance at board and committee meetings, communication with auditors, supervision of information disclosure, governance, and protection of minority shareholders' rights during the 2024 fiscal year. The content is a detailed report of the independent director's activities and responsibilities over the year, not an announcement or a brief notice. It is not a full annual report (10-K) or audit report (AR), but rather a management-related report focusing on board and governance activities. This fits best under Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management. The document is 2745 characters, which is relatively short but contains substantive content about the independent director's work, not just an announcement of a report. Therefore, the classification is MANG with high confidence.
2025-04-22 Chinese
2024年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report' and is issued by Beijing Dehao International Certified Public Accountants. It includes detailed audit opinions, financial statements (balance sheet, income statement, cash flow statement, equity changes), notes to the financial statements, and explanations of audit procedures and responsibilities. The period covered is the full fiscal year 2024 (January 1 to December 31, 2024). The content is comprehensive and contains actual financial data and audit findings, not just an announcement or certification. Therefore, this document fits the category of a standalone Audit Report / Information filing rather than a full Annual Report or other categories. FY 2024
2025-04-22 Chinese
董事会关于独立董事独立性情况的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion from the board regarding the independence of the company's independent directors. It references compliance with regulatory rules about independent directors and assesses their independence based on various criteria. There is no financial data, no report attached or referenced, and no indication of a meeting or voting results. This is a governance-related announcement about board members' independence, which fits best under Board/Management Information (MANG) as it concerns board member status and qualifications.
2025-04-22 Chinese
北京星昊医药股份有限公司内部控制审计报告
Audit Report / Information Classification · 100% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by an accounting firm (Beijing Dehao International Certified Public Accountants) and addresses the effectiveness of internal controls over financial reporting as of December 31, 2024. The content includes auditor responsibilities, inherent limitations of internal control, and an audit opinion on the effectiveness of internal controls. This is a standalone audit report focused on internal control over financial reporting, not a full annual report or interim financial report. The document length is 5233 characters, which is sufficient to contain substantive audit content rather than just an announcement. Therefore, the document fits the category of Audit Report / Information (AR). FY 2024
2025-04-22 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.